{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Infectious Complications of Newer Agents in the Fight Against Diabetes

Activity Steps

Purpose of Activity

To provide information about infectious complications associated with three newer antidiabetic medication classes that include GLP-1 RAs, SGLT2 inhibitors, and DPP-4 inhibitors.

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Describe the prevalence and complications of diabetes in the US and the mechanism of action for each of the three newer antidiabetic medication classes.
  2. Identify infectious complications associated with use of GLP-1 RAs, SGLT2 inhibitors, and DPP-4 inhibitors.
  3. Summarize diabetes treatment recommendations for the newer antidiabetic medication classes.
Price: $17.95


  • ANCC 1.5 CH / 1.5 APH
  • DC - BON 1.5 CH
  • FL - BON 1.5 CH
  • GA - BON 1.5 CH

Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.

Awarded Advanced Pharmacology Hours

Test Code: NP1120B
Published: Nov 2020
Expires: 9/2/2022
Required Passing Score: 14/20 (70%)
Authors: Kayla R. Stover, PharmD; Emily Hugh, PharmD; Justin J. Sherman, PharmD, MCS; Scott S. Malinowski, PharmD; Gideon J. Berdahl, PharmD; Daniel M. Riche, PharmD